We all know exercise is good for us — it's why we keep persevering when it starts to feel really hard. Moving your body is important for heart health, wellbeing, and maintaining a healthy weight. But exercise also has benefits for your brain, and …

Biogen’s sales for its new Alzheimer’s drug fell short of Wall Street expectations, with the drugmaker reporting on Wednesday that it brought in millions less than anticipated from Aduhelm in the third quarter. The first Alzheimer’s drug approved by the …

(MENAFN- GlobeNewsWire - Nasdaq) -Topline data targeted for 1H22- BOTHELL, Wash., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore …

The drugmaker Biogen Inc. reported Wednesday that Aduhelm, its new Alzheimer's drug, had brought in $300,000 in revenue from July to September, far short of the company's goals and Wall Street's expectations. The sales figures, which Biogen …

PORTLAND, OR, UNITED STATES, October 22, 2021 /⁨EINPresswire.com⁩/ -- Most of the college students, professionals, and entrepreneurs are using smart drugs to maximize their mental capabilities. For instance, Piracetam improves memory in seniors …

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations. The sales figures, which Biogen disclosed in its …

A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, continuing a slow debut complicated by coverage questions and concerns from doctors.The infused drug, hailed as a potential breakthrough …

FILE - This image provided by Biogen on Monday, June 7, 2021 shows a vial and packaging for the drug Aduhelm. The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it in June 2021, but its rollout …

Uptake for Aduhelm, the newest approved drug for Alzheimer’s disease, remained slow over the summer, and sales could be minimal through the end of the year, drugmaker Biogen Inc. said Wednesday. The Cambridge, Mass.-based pharmaceutical company said its …

By Manas Mishra and Dania Nadeem (Reuters) -Biogen Inc is pinning its hopes on a decision on U.S. government coverage of its Alzheimer's disease drug next year to help drive up its usage, after a big miss on quarterly sales of the much-awaited …